Agriculture company Calyxt Inc (NASDAQ: CLXT) announced on Thursday that it plans to crush and produce its high oleic soybean variety through an agreement with American Natural Processors (ANP), a leading provider of innovative non-GMO and organic processing of oils, flours and meals in Cherokee, Iowa.
ANP will crush Calyxt's high-oleic soybean variety and produce its first high oleic consumer soybean oil, which is expected to hit the market in late 2018 / early 2019.
In conjunction, the high-oleic / low-saturated fat oil from Calyxt's new variety of soybeans is designed to eliminate the need for hydrogenation, a process that improves heat stability and shelf life of conventional soybean oil. The process of hydrogenation for conventional soybean oil contributes to the production of trans-fatty acids, which, when consumed, raises low-density lipoprotein, or LDL, and cholesterol levels, as well as contributes to cardiovascular diseases.
Additionally, Calyxt has received a letter from the USDA confirming that its high-oleic soybean variety is non-regulated, as the product contains no foreign DNA.
The US FDA has declared trans fats not generally recognised as safe (GRAS) and human food must no longer contain partially hydrogenated oils by 18 June 2018. The World Health recently unveiled a plan to remove all trans fats worldwide from the food chain by 2023.
LivaNova announces commercial launch of Essenz Perfusion System in China
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
GEN and Sulfateq report positive Phase 1 data for SUL-238 in Alzheimer's
Philips launches ECG AI Marketplace to streamline cardiac diagnostics
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement